CAR-NK019（Second Affiliated Hospital, School of Medicine, Zhejiang University）

N/A

Report date: 2022/07/01 14:25:06

Base Information

Drug NameCAR-NK019（Second Affiliated Hospital, School of Medicine, Zhejiang University）
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Zhejiang University School Of MedicineSecond Affiliated Hospital School Of Zhejiang University School Of Medicine
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A